Thursday, January 10, 2013
The FDA issued a draft guidance document to assist industry in developing new formulations of opioid drugs with abuse-deterrent properties. The document, titled "Guidance for Industry: Abuse-Deterrent Opioids Evaluation and Labeling," contains the agency's current thinking about the studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.